Form 8-K - Current report:
SEC Accession No. 0001437749-21-022018
Filing Date
2021-09-13
Accepted
2021-09-13 16:09:27
Documents
16
Period of Report
2021-09-09
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20210913_8k.htm   iXBRL 8-K 31642
2 EXHIBIT 99.1 ex_283424.htm EX-99.1 35443
7 a01.jpg GRAPHIC 7841
8 ex_283424img001.jpg GRAPHIC 29298
  Complete submission text file 0001437749-21-022018.txt   265230

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20210909.xsd EX-101.SCH 3593
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20210909_def.xml EX-101.DEF 11807
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20210909_lab.xml EX-101.LAB 15858
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20210909_pre.xml EX-101.PRE 12022
9 EXTRACTED XBRL INSTANCE DOCUMENT dffn20210913_8k_htm.xml XML 2662
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 211249780
SIC: 2834 Pharmaceutical Preparations